Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts
The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study. Aardvark was studying the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader …